Apitegromab
- Generic Name
- Apitegromab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2278276-46-1
- Unique Ingredient Identifier
- UZ54216N0Y
- Background
Apitegromab is under investigation in clinical trial NCT03921528 (An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy).
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
- Conditions
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Scholar Rock, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06445075
- Locations
- ๐บ๐ธ
ProSciento CRU, Chula Vista, California, United States
๐บ๐ธAdventHealth Translational Research Institute, Orlando, Florida, United States
๐บ๐ธGreat Lakes Clinical Trials, LLC d/b/a Flourish Research, Chicago, Illinois, United States
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab-ONYX
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Scholar Rock, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT05626855
- Locations
- ๐ง๐ช
UZ Gent, Gent, Belgium
๐ง๐ชCHR Citadelle, Liege, Belgium
๐ซ๐ทHopital Trousseau - I-Motion, Paris, France
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Scholar Rock, Inc.
- Target Recruit Count
- 188
- Registration Number
- NCT05156320
- Locations
- ๐บ๐ธ
Oregon Health & Sciences University, Portland, Oregon, United States
๐บ๐ธChildren's Hospital Colorado, Aurora, Colorado, United States
๐บ๐ธChildren's Hospital of Los Angeles, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.